Literature DB >> 18607390

A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1.

Huiming Sheng1, Ying Wang, Yuqing Jin, Qiuyu Zhang, Yan Zhang, Li Wang, Baihua Shen, Shuo Yin, Wei Liu, Lei Cui, Ningli Li.   

Abstract

Bone-marrow-derived mesenchymal stem cells (MSCs) have been shown to possess immunosuppressive properties, e.g., by inhibiting T cell proliferation. Activated T cells can also enhance the immunosuppression ability of MSCs. The precise mechanisms underlying MSC-mediated immunosuppression remain largely undefined, although both cell-cell contact and soluble factors have been implicated; nor is it clear how the immunosuppressive property of MSCs is modulated by T cells. Using MSCs isolated from mouse bone marrow, we show here that interferon gamma (IFNgamma), a well-known proinflammatory cytokine produced by activated T cells, plays an important role in priming the immunosuppressive property of MSCs. Mechanistically, IFNgamma acts directly on MSCs and leads to up-regulation of B7-H1, an inhibitory surface molecule in these stem cells. MSCs primed by activated T cells derived from IFNgamma-/- mouse exhibited dramatically reduced ability to suppress T cell proliferation, a defect that can be rescued by supplying exogenous IFNgamma. Moreover, siRNA-mediated knockdown of B7-H1 in MSCs abolished immunosuppression by these cells. Taken together, our results suggest that IFNgamma plays a critical role in triggering the immunosuppresion by MSCs through up-regulating B7-H1 in these cells, and provide evidence supporting the cell-cell contact mechanism in MSC-mediated immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607390     DOI: 10.1038/cr.2008.80

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  146 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 2.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 3.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

Authors:  Igor B Resnick; Claudine Barkats; Michael Y Shapira; Polina Stepensky; Allan I Bloom; Avichai Shimoni; David Mankuta; Nira Varda-Bloom; Lyudmila Rheingold; Moshe Yeshurun; Bella Bielorai; Amos Toren; Tsila Zuckerman; Arnon Nagler; Reuven Or
Journal:  Am J Blood Res       Date:  2013-08-19

5.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

6.  Mesenchymal stem cells: Molecular characteristics and clinical applications.

Authors:  Farbod Rastegar; Deana Shenaq; Jiayi Huang; Wenli Zhang; Bing-Qiang Zhang; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Qing Luo; Qiong Shi; Eric R Wagner; Enyi Huang; Yanhong Gao; Jian-Li Gao; Stephanie H Kim; Jian-Zhong Zhou; Yang Bi; Yuxi Su; Gaohui Zhu; Jinyong Luo; Xiaoji Luo; Jiaqiang Qin; Russell R Reid; Hue H Luu; Rex C Haydon; Zhong-Liang Deng; Tong-Chuan He
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 7.  The role of recipient T cells in mesenchymal stem cell-based tissue regeneration.

Authors:  Yi Liu; Songlin Wang; Songtao Shi
Journal:  Int J Biochem Cell Biol       Date:  2012-08-09       Impact factor: 5.085

8.  Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis.

Authors:  Evelien Schurgers; Hilde Kelchtermans; Tania Mitera; Lies Geboes; Patrick Matthys
Journal:  Arthritis Res Ther       Date:  2010-02-22       Impact factor: 5.156

9.  Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.

Authors:  S Jyothi Prasanna; Divya Gopalakrishnan; Shilpa Rani Shankar; Anoop Babu Vasandan
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity.

Authors:  Anahid Jewett; Aida Arasteh; Han-Ching Tseng; Armin Behel; Hobie Arasteh; Wendy Yang; Nicholas A Cacalano; Avina Paranjpe
Journal:  PLoS One       Date:  2010-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.